文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 自然科学 > 生物学 > Immune response to dengue virus and prospects for a vaccine
侵权投诉

Immune response to dengue virus and prospects for a vaccine

ANNUAL REVIEWS

Click here for quick links to Annual Reviews content online, including: Other articles in this volume Top cited articles Top downloaded articles Our comprehensive search

Further

Immune Response to Dengue Virus and Prospects for a Vaccine Brian R. Murphy and Stephen S. Whitehead Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892; email: swhitehead@niaid.nih.gov

Annu. Rev. Immunol. 2011.29:587-619. Downloaded from doc.guandang.net by Shanghai Information Center for Life Sciences on 12/02/13. For personal use only.

Annu. Rev. Immunol. 2011. 29:587–619 First published online as a Review in Advance on January 5, 2011 The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev-immunol-031210-101315 0732-0582/11/0423-0587$20.00

Keywords DENV, antibody-dependent enhancement, DHF/DSS, immunization

Abstract Dengue virus (DENV) is a mosquito-borne member of the Flavivirus genus and includes four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), each of which is capable of causing dengue fever and dengue hemorrhagic fever/dengue shock syndrome. Serious disease can be seen during primary infection but is more frequent following second infection with a serotype different from that of a previous infection. Infection with wild-type DENV induces high-titered neutralizing antibody that can provide long-term immunity to the homotypic virus and can provide short-term immunity (only several months duration) to a heterotypic DENV. The high level of virus replication seen during both secondary infection with a heterotypic virus and during primary DENV infection in late infancy is a direct consequence of antibody-dependent enhancement of replication. This enhanced virus replication is mediated primarily by preexisting, nonneutralizing, or subneutralizing antibodies to the virion surface antigens that enhance access of the virion-antibody complex to FcγR-bearing cells. Vaccines will need to provide longterm protection against each of the four DENV serotypes by inducing neutralizing antibodies, and live, attenuated and various nonliving virus vaccines are in development.

This is a work of the U.S. Government and is not subject to copyright protection in the United States.

587

Immune response to dengue virus and prospects for a vaccine

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email